{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fluticasone+furoate+%28FF%29&page=2", "query": { "intervention": "fluticasone furoate (FF)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 47, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fluticasone+furoate+%28FF%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fluticasone+furoate+%28FF%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T09:17:58.266Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01894386", "title": "Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF 400 mcg", "type": "DRUG" }, { "name": "UMEC 500 mcg", "type": "DRUG" }, { "name": "UMEC 250 mcg", "type": "DRUG" }, { "name": "VI 100 mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2013-07-15", "completion_date": "2013-09-26", "has_results": false, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01894386" }, { "nct_id": "NCT05757102", "title": "A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FF/UMEC/VI", "type": "DRUG" }, { "name": "ELLIPTA", "type": "DEVICE" }, { "name": "FF/VI", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 138, "start_date": "2023-04-24", "completion_date": "2027-01-28", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05757102" }, { "nct_id": "NCT02483975", "title": "Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Albuterol/Salbutamol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "5 Years to 11 Years" }, "enrollment_count": 111, "start_date": "2015-10-09", "completion_date": "2016-06-21", "has_results": true, "last_update_posted_date": "2020-04-27", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02483975" }, { "nct_id": "NCT01627327", "title": "Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "fluticasone furoate/vilanterol 100/25mcg", "type": "DRUG" }, { "name": "tiotropium bromide 18mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 623, "start_date": "2012-04-01", "completion_date": "2012-12-21", "has_results": true, "last_update_posted_date": "2017-11-09", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 11, "location_summary": "Newport Beach, California • Coeur d'Alene, Idaho • Charlotte, North Carolina + 8 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Medford", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01627327" }, { "nct_id": "NCT00774761", "title": "A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "fluticasone propionate/formoterol fumarate", "type": "DRUG" }, { "name": "fluticasone propionate", "type": "DRUG" }, { "name": "formoterol fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dey", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 97, "start_date": "2008-11", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2013-05-20", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 12, "location_summary": "San Diego, California • Panama City, Florida • Madisonville, Kentucky + 9 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Panama City", "state": "Florida" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "Sunset", "state": "Louisiana" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00774761" }, { "nct_id": "NCT01323621", "title": "Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg", "type": "DRUG" }, { "name": "Fluticasone Propionate 250mcg / salmeterol 50mcg", "type": "DRUG" }, { "name": "Double-dummy placebo", "type": "DRUG" }, { "name": "Salbutamol as needed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 512, "start_date": "2011-03-18", "completion_date": "2012-01-24", "has_results": true, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 13, "location_summary": "Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Riverside", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323621" }, { "nct_id": "NCT01686633", "title": "An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone Furoate/ Vilanterol 200/25 mcg", "type": "DRUG" }, { "name": "Fluticasone Furoate/ Vilanterol 100/25 mcg", "type": "DRUG" }, { "name": "Fluticasone Furoate 100 mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1040, "start_date": "2012-09-20", "completion_date": "2013-10-15", "has_results": true, "last_update_posted_date": "2018-01-24", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 37, "location_summary": "Little Rock, Arkansas • Huntington Beach, California • Los Angeles, California + 33 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Rancho Mirage", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01686633" }, { "nct_id": "NCT01009463", "title": "A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF/GW642444 Inhalation Powder", "type": "DRUG" }, { "name": "GW642444 Inhalation Powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1626, "start_date": "2009-09-25", "completion_date": "2011-10-31", "has_results": true, "last_update_posted_date": "2017-11-09", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 94, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01009463" }, { "nct_id": "NCT02119286", "title": "Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF", "type": "DRUG" }, { "name": "VI", "type": "DRUG" }, { "name": "UMEC", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 620, "start_date": "2013-10", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 14, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02119286" }, { "nct_id": "NCT02105974", "title": "Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate/Vilanterol", "type": "DRUG" }, { "name": "Vilanterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1621, "start_date": "2014-04-07", "completion_date": "2015-07-08", "has_results": true, "last_update_posted_date": "2018-01-24", "last_synced_at": "2026-10-04T09:17:58.266Z", "location_count": 17, "location_summary": "Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "Sunset", "state": "Louisiana" }, { "city": "Saint Charles", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02105974" } ] }